7-Chlorokynurenic acid
CAS No. 18000-24-3
7-Chlorokynurenic acid( 7-CKA | 7-chloro-4-hydroxy-2-carboxyquinoline )
Catalog No. M26039 CAS No. 18000-24-3
7-Chlorokynurenic acid is an effecitve and selective antagonist of NMDA receptor with IC50 of 0.56 μM for the glycine B coagonist site.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 34 | In Stock |
|
| 10MG | 55 | In Stock |
|
| 25MG | 115 | In Stock |
|
| 50MG | 221 | In Stock |
|
| 100MG | 426 | In Stock |
|
| 500MG | 888 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name7-Chlorokynurenic acid
-
NoteResearch use only, not for human use.
-
Brief Description7-Chlorokynurenic acid is an effecitve and selective antagonist of NMDA receptor with IC50 of 0.56 μM for the glycine B coagonist site.
-
Description7-Chlorokynurenic acid is an effecitve and selective antagonist of NMDA receptor with IC50 of 0.56 μM for the glycine B coagonist site. 7-Chlorokynurenic acid inhibits the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM and shows antinociceptive actions after neuraxial delivery.(In Vivo):In male Sprague-Dawley rats, 7-Chlorokynurenic acid (10 nM) retardates the development of both the electroencephalographic and motor (17.7 daily stimulations) components of the seizure response.
-
In Vitro——
-
In VivoMale Sprague-Dawley rats pretreated with 7-Chlorokynurenic acid (10 nM) shows a significant retardation of development of both the electroencephalographic and motor (17.7±2.9 daily stimulations) components of the seizure response.
-
Synonyms7-CKA | 7-chloro-4-hydroxy-2-carboxyquinoline
-
PathwayNeuroscience
-
TargetGluR
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number18000-24-3
-
Formula Weight223.61
-
Molecular FormulaC10H6ClNO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 16.67 mg/mL (74.55 mM)
-
SMILESO=C(O)C=1N=C2C=C(Cl)C=CC2=C(O)C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Okusaka T, Ueno H, Ikeda M, Takezako Y, Morizane C. Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. Cancer Sci. 2012 Aug;103(8):1524-30. doi: 10.1111/j.1349-7006.2012.02334.x. Epub 2012 Jun 18. PubMed PMID: 22587457.
molnova catalog
related products
-
DNQX
DNQX is a competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5 and 0.1 μM for AMPA and kainate receptors respectively).
-
LY404187
LY404187 is a positive allosteric modulator of AMPA receptors.
-
(S)-MCPG
(S)-MCPG ((+)-MCPG) is a class I/II metabotropic glutamate receptors (mGluRs) antagonist that blocks spatial learning and long-term enhancement of the dentate gyrus in vivo in rats, and can be used to study neurological disorders.
Cart
sales@molnova.com